{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '4. Willing and able to comply with the study requirements and to provide written informed', 'consent and assent in the case of patients under the age of legal consent, per local and', 'national requirements.', '5.2.', 'Exclusion Criteria', 'Each patient must not meet any of the following exclusion criteria to be eligible for enrollment in', 'the study:', '1. Known co-existing bleeding disorders other than hemophilia A or B, ie, Von', \"Willebrand's disease, additional factor deficiencies, or platelet disorders.\", '2. Current participation in immune tolerance induction therapy (ITI)', '3.', 'Current use of BPAs as regularly administered prophylaxis designed to prevent', 'spontaneous bleeding episodes.', '4. AT activity <60% at Screening, as determined by central laboratory measurement.', '5. Presence of clinically significant liver disease, or as indicated by any of the conditions', 'below:', 'a. INR >1.2', 'b. ALT and/or AST >1.5x upper limit of normal reference range (ULN);', \"c. Total bilirubin >ULN (>1.5x ULN in patients with Gilbert's Syndrome);\", 'd. History of portal hypertension, esophageal varices, or hepatic encephalopathy;', 'e. Presence of ascites by physical exam', '6. Hepatitis C virus antibody positive, except patients with a history of HCV infection who', 'meet both conditions a. and b.:', 'a. Completed curative treatment at least 12 weeks prior to enrollment and attained', 'sustained virologic response as documented by a negative HCV RNA at', 'screening, or they have spontaneously cleared infection as documented by', 'negative HCV RNA at Screening.', 'b. No evidence of cirrhosis according to one of the following assessments:', '- FibroScan <12.5 kPa (where available), or', '- FibroTest score <0.75 and APRI <2 (if FibroScan unavailable)', '7. Presence of acute hepatitis, ie, hepatitis A, hepatitis E.', '8. Presence of acute or chronic hepatitis B infection (IgM anti-HBc antibody positive or', 'HBs Ag positive).', '9. Platelet count <100,000/uL.', '10. Presence of acute infection at Screening.', '11. Known to be HIV positive with CD4 count <200 cells/L.', '12. Estimated glomerular filtration rate <45 mL/min/1.73 m\u00b2 (using the Modification of Diet', 'in Renal Disease [MDRD] formula).', 'Property of the Sanofi Group - strictly confidential', '39']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '13. Co-existing thrombophilic disorder, as determined by presence of any of the below as', 'identified at central laboratory (or via historical results, where available):', 'a. FV Leiden mutation (homozygous or heterozygous)', 'b. Protein S deficiency', 'c. Protein C deficiency', 'd. Prothrombin mutation (G20210A; homozygous or heterozygous)', '14. History of antiphospholipid antibody syndrome.', '15. History of arterial or venous thromboembolism, atrial fibrillation, significant valvular', 'disease, myocardial infarction, angina, transient ischemic attack, or stroke. Patients who', 'have experienced thrombosis associated with indwelling venous access may be enrolled.', '16. Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin', 'that has been successfully treated.', '17. Any condition (eg, medical concern), which in the opinion of the Investigator, would', 'make the patient unsuitable for dosing on Day 1 or which could interfere with the study', \"compliance, the patient's safety and/or the patient's participation in the completion of the\", 'treatment period of the study. This includes significant active and poorly controlled', '(unstable) cardiovascular, neurologic, gastrointestinal, endocrine, renal or psychiatric', 'disorders unrelated to hemophilia identified by key laboratory abnormalities or medical', 'history.', '18. At Screening, anticipated need of surgery during the study or planned surgery scheduled', 'to occur during the study.', '19. Completion of a surgical procedure within 14 days prior to Screening, or currently', 'receiving additional BPA infusion for postoperative hemostasis.', '20. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or', 'GalNAc.', '21. Inadequate venous access, as determined by the Investigator, to allow the blood draws', 'required by the study protocol.', '22. History of intolerance to SC injection(s).', '23. Current or future participation in another clinical study, scheduled to occur during this', 'study, involving an investigational product other than fitusiran or an investigational', 'device; in order to participate in this study, patient must discontinue the investigational', 'product or investigational device at least 30 days (or 5x the investigational product half-', 'life, whichever is longer) prior to dosing (Day 1).', '24. Current or prior participation in a gene therapy trial.', '25. History of alcohol abuse within the 12 months before Screening. Alcohol abuse is', 'defined as regular weekly intake of more than 14 units (unit: 1 glass of wine', '[approximately 125 mL] = 1 measure of spirits (approximately 1 fluid ounce) = 1/2 pint of', 'beer [approximately 284 mL]).', 'Property of the Sanofi Group - strictly confidential', '40']\n\n###\n\n", "completion": "END"}